These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 11776248)
1. [PolyEnv, a new strategy in the development of anti-HIV vaccines]. Molina CN Sidahora; 2001 Oct; ():7-11. PubMed ID: 11776248 [No Abstract] [Full Text] [Related]
2. HIV vaccines: new frontiers in vaccine development. Duerr A; Wasserheit JN; Corey L Clin Infect Dis; 2006 Aug; 43(4):500-11. PubMed ID: 16838241 [TBL] [Abstract][Full Text] [Related]
3. The search for effective HIV vaccines. Markel H N Engl J Med; 2005 Aug; 353(8):753-7. PubMed ID: 16120854 [No Abstract] [Full Text] [Related]
4. An HIV vaccine--challenges and prospects. Johnston MI; Fauci AS N Engl J Med; 2008 Aug; 359(9):888-90. PubMed ID: 18753644 [No Abstract] [Full Text] [Related]
5. Inclusion of the viral anti-apoptotic molecule M11L in DNA vaccine vectors enhances HIV Env-specific T cell-mediated immunity. Su J; Willert C; Comanita L; Peters A; Gilbert PA; Strathdee C; O'Connell PJ; McFadden GD; Dekaban GA Virology; 2008 May; 375(1):48-58. PubMed ID: 18291435 [TBL] [Abstract][Full Text] [Related]
8. Researchers announce first correlates of protection for HIV vaccine. Roehr B BMJ; 2011 Sep; 343():d5880. PubMed ID: 21920885 [No Abstract] [Full Text] [Related]
9. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Ferrantelli F; Cafaro A; Ensoli B Curr Opin Biotechnol; 2004 Dec; 15(6):543-56. PubMed ID: 15560981 [TBL] [Abstract][Full Text] [Related]
10. [Biotechnology vaccines--development of new disease prevention. Research progress of Biocine in Siena--HIV, herpes, Helicobacter]. Keil TU Fortschr Med; 1994 Apr; 112(11):53-4. PubMed ID: 8200601 [No Abstract] [Full Text] [Related]
11. Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines. Robinson HL; Weinhold KJ J Infect Dis; 2006 Dec; 194(12):1625-7. PubMed ID: 17109331 [No Abstract] [Full Text] [Related]
12. CTL ontogeny and viral escape: implications for HIV-1 vaccine design. Yang OO Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041 [No Abstract] [Full Text] [Related]
13. AIDS 1997. Vaccines and immunology: overview. Hu S; Norrby E AIDS; 1997; 11 Suppl A():S85-6. PubMed ID: 9451971 [No Abstract] [Full Text] [Related]
14. New strategies to combat HIV: augmenting antiviral immunity. Smith KA; Boyle BA AIDS Read; 2003 Aug; 13(8):365-9, 382. PubMed ID: 14524321 [No Abstract] [Full Text] [Related]
16. HIV/AIDS in China. Vaccine development with a distinctly Chinese flavor. Cohen J Science; 2004 Jun; 304(5676):1437. PubMed ID: 15178780 [No Abstract] [Full Text] [Related]
17. HIV-1/AIDS vaccine development: are we in the darkness. Qiu C; Xu JQ Chin Med J (Engl); 2008 May; 121(10):939-45. PubMed ID: 18706210 [No Abstract] [Full Text] [Related]
18. HIV vaccine may raise risk. Ledford H Nature; 2007 Nov; 450(7168):325. PubMed ID: 18004331 [No Abstract] [Full Text] [Related]
19. HIV immunology needs a new direction. Medzhitov R; Littman D Nature; 2008 Oct; 455(7213):591. PubMed ID: 18833256 [No Abstract] [Full Text] [Related]
20. Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Altfeld M; Allen TM Trends Immunol; 2006 Nov; 27(11):504-10. PubMed ID: 16997629 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]